Aptose Biosciences (APTO) said Monday that it has regained compliance with Nasdaq's minimum bid price requirement.
The company said it received a written notice for the compliance from the stock exchange on Friday after having a closing bid price of $1 or greater for 10 consecutive business days.
Aptose also said it is not in compliance with the $2.5 million stockholders' equity requirement of Nasdaq and is operating under an exception granted by the hearing panel of the stock exchange, which allows for additional time to regain compliance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。